← Back to headlines
Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy
Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.
22 May, 08:44 — 22 May, 08:44
